Zimmer Biomet Reports 9.7% Revenue Growth in Q3 2025, Net Earnings Decline

Zimmer Biomet Holdings, Inc. reported a notable increase in financial performance for the third quarter of 2025, with net sales reaching $2,001.4 million, a 9.7% increase from $1,824.2 million in the same period last year. For the nine months ending September 30, 2025, net sales totaled $5,987.7 million, up 5.9% from $5,655.4 million in 2024. The growth was attributed to the acquisition of Paragon 28, which contributed 3.6% and 2.1% to sales growth in the respective three and nine-month periods, alongside favorable foreign currency exchange impacts.

Despite the revenue growth, net earnings for the third quarter decreased to $230.9 million from $249.1 million year-over-year, while nine-month net earnings fell to $565.8 million from $664.3 million. The decline in earnings was primarily due to increased costs associated with the Paragon 28 acquisition, higher interest expenses, and investments in marketing and technology. Additionally, the previous year’s figures included a tax benefit from an agreement with the IRS, which did not recur in 2025.

Strategically, Zimmer Biomet has been active in expanding its market presence through acquisitions, including the recent purchase of Monogram Technologies, an orthopedic robotics company, for approximately $180 million. This acquisition is expected to enhance Zimmer Biomet's capabilities in robotic technologies. The company also completed the acquisition of Paragon 28 earlier in 2025, which is anticipated to strengthen its position in the foot and ankle orthopedic segment.

Operationally, Zimmer Biomet's customer base and product adoption rates have shown positive trends. The company reported significant sales growth across its product categories, particularly in Sports Medicine, Extremities, Trauma, and Craniomaxillofacial and Thoracic (S.E.T.), which saw a 19.2% increase in the third quarter. The Americas segment generated $1,253.5 million in sales, a 10.4% increase from the previous year, while international sales rose by 8.5%. The company also reported a decrease in restructuring costs, reflecting the successful implementation of its restructuring plans.

Looking ahead, Zimmer Biomet anticipates full-year revenue growth of 6.7% to 7.7% for 2025, driven by the contributions from the Paragon 28 acquisition and new product introductions. However, the company expects net earnings to decline due to higher acquisition-related costs, increased operating expenses, and a higher effective tax rate. The company is also preparing for potential impacts from tariffs, estimating an additional $40 million in expenses for 2025. Overall, Zimmer Biomet remains focused on leveraging its acquisitions and operational efficiencies to drive future growth.